High sensitivity cardiac troponin assays 2009: clinical potential, current practice and benefits, the future

Czech version

Authors: M. Engliš ¹; J. Šochman ²; R. Pudil ³; J. Franeková ⁴; A. Jabor ⁴
Authors‘ workplace: Oddělení klinické biochemie Fakultní Thomayerovy nemocnice Praha, přednostka prim. MU Dr. Zora Hamrlová ¹; Klinika kardiologie IKEM Praha, přednosta prof. MU Dr. Jan Kautzner, CSc., FESC ²; I. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Jan Vojáček, DrSc., FESC, FACC ³; Pracoviště laboratorních metod IKEM Praha, přednosta prof. MU Dr. Antonín Jabor, CSc. ⁴
Published in: Vnitř Lék 2009; 55(11): 1079-1084
Category: Reviews

Overview

At present, determination of cardiac troponins (cTn) is the biomarker method of choice for diagnostics and risk stratification in patients with a myocardial injury. Past clinical practice had provided sound evidence that low cTn concentrations, measured with unacceptable imprecision by the currently used methods, hold important clinical, diagnostic and stratification potential. The new generation cTn assays, so called high‑sensitivity assays, enable determination of very low cTn concentrations with satisfactory analytical precision and open the way to early identification of small but often prognostically important myocardial damage. Introduction of high‑sensitivity cTn assays in practice is, however, associated with some difficulties: their superior diagnostic sensitivity to identify small injuries to myocardium is often linked to lower specificity, higher incidence of elevated cTn concentrations is frequently associated with less obvious clinical symptomatology (overdiagnosis), resulting in greater demand for further patient assessment (overcrowding), repeated analyses and trend monitoring of cTn fluctuation. These initial difficulties cannot lessen the by now indisputable, established benefit of high‑sensitivity cTn assays that we briefly describe in the present paper.

Key words:
high‑sensitivity cardiac troponin assays – criteria for evaluation – established benefit for clinical practice – initial difficulties

Sources

1. Alpert J, Thygesen K, Bassand J et al. ESC/ ACC Myocardial infarction redefined. J Am Coll Cardiol 2000; 36: 959– 969.

2. Apple FS, Jesse RL, Newby LK et al. NACB/ IFCC: Analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 2007; 115: e352– e355.

3. Apple FS, Pearce LA, Smith SW et al. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem 2009; 55: 930– 937.

4. Apple FS. A new season for cardiac troponin assays: It’s time to keep a scorecard. Clin Chem 2009; 55: 1303– 1306.

5. Baum H et al. Roche Diagnostics (2002); G. Klein, osobní sdělení.

6. Braunwald E, Antman EM, Beaslay JW et al. ACC/ AHA Guidelines for the management of patients with unstable angina and non‑ST‑segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193– 1209.

7. Eggers KM, Lagergvist B, Venge P et al. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long‑term mortality. Circulation 2007; 116: 1907– 1914.

8. Eggers KM, Lagergvist B, Oldgren J et al. Pathophysiologic mechanisms of persisted cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndromes. Am Heart J 2008; 156: 588– 594.

9. Eggers KM, Lind L, Ahlström H et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population‑based sample of elderly subjects. Eur Heart J 2008; 29: 2252– 2258.

10. Eggers KM, Jaffe AS, Lind L et al. Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision- making. Clin Chem 2009; 55: 85– 92.

11. Eggers KM, Lind L, Venge P et al. Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol 2009; 103: 588– 591.

12. Engliš M, Šochman J. Srdeční troponiny v klinické praxi. Tac‑ Tac Agency Publ 2009; 22– 28: 53– 54.

13. Engliš M. Vlastní pozorování. 2009.

14. Giannitsis E et al. Roche proCardio Symp (2009), Barcelona, osobní sdělení.

15. Guigliano RP, White JA, Bode C et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360: 2176– 2190.

16. Hessel MH, Atsma DE, van der Valk EJ et al. Release of cardiac troponin I from viable cardiomyocytes mediated by integrin stimulation. Pflugers Arch 2008; 455: 979– 986.

17. Hildebrandt P et al. Roche proCardio Symp (2009), Barcelona, osobní sdělení.

18. Hillis LD, Lange RA. Optimal management of acute coronary syndromes. N Engl J Med 2009; 360: 2237– 2240.

19. Chen Y, Serfass RC, Mackey‑ Bojack SM et al. Cardiac troponin T alterations in myocardium and serum of rats after stressful prolonged intense exercise. J Appl Physiol 2000; 88: 1749– 1755.

20. Jacobs LH, van de Kerkhof J, Mingels AM et al. Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponinT and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem 2009; 46: 283– 290.

21. Jarausch J. Roche hs‑ TnT Pilot Study (2008).

22. Katus HA, Giannitsis E, Jaffe AS et al. Higher sensitivity troponin assays: Quo vadis? Eur Heart J 2009; 30: 127– 128.

23. Kavsak PA, MacRae AR, Yerna MJ et al. Analytic and clinical utility of a next‑ generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem 2009; 55: 573– 577.

24. Kurz K, Giannitsis E, Zehelein J et al. Highly sensitive cardiac troponin T values remain constant after brief exercise or pharmacologic‑induced reversible myocardial ischemia. Clin Chem 2008; 54: 1234– 1238.

25. Leers MP, Schepers R, Baumgarten R et al. Effects of a long‑distance run on cardiac markers in healthy athletes. Clin Chem Lab Med 2006; 44: 999– 1003.

26. Lippi G, Montagnana M, Guidi GC. The clinical dilemma of positive results of high‑sensitive troponin assays. Am J Cardiol 2009; 103: 1332.

27. Mehta SR, Granger CB, Boden WE et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165– 2175.

28. Middleton N, George K, Whyte G et al. Cardiac troponin T release is stimulated by endurance exercise in healthy humans. J Am Coll Cardiol 2008; 52: 1813– 1814.

29. Mingels A, Jacobs L, Michielsen E et al. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009; 55: 101– 108.

30. Neizel M, Steen H, Korosoglou G et al. Minor troponin T elevation in patients 6 months after acute myocardial infarction: an observational study. Clin Res Cardiol 2009; 98: 297– 304.

31. Panteghini M, Pagani F, Yeo KT et al. Evaluation of imprecision for cardiac troponin assays at low‑ range concentrations. Clin Chem 2004; 50: 327– 332.

32. Reichlin T, Hochholzer W, Bassetti S et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858– 867.

33. Roche Diagnostics: Prelimitary results of multicenter evaluation of the Elecsys troponin T high sensitive (2008).

34. Sabatine MS, Morrow DA, de Lemos JA et al. Detection of acute changes in circulating troponin in setting of transient stress test‑induced myocardial ischemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009; 30: 162– 169.

35. Saenz AJ, Lee‑ Lewandrowski E, Wood MJ et al. Measurement of plasma stroke biomarker panel and cardiac troponin T in marathon runners before and after the 2005 Boston marathon. Am J Clin Pathol 2006; 126: 185– 189.

36. Sundström J, Ingelsson E, Berglund L et al. Cardiac troponin‑I and risk of heart failure: a community based cohort study. Eur Heart J 2009; 30: 773– 781.

37. Tate JR. Troponin revisited 2008: assay performance. Clin Chem Lab Med 2008; 46: 1489– 1500.

38. Thygesen K, Alpert JS, Whide HD et al. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173– 2195.

39. Venge P, Johnston N, Lindahl B et al. Normal plasma levels of cardiac troponin I meassured by the high‑sensitivity cardiac access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009; 54: 1165–1172.

40. Wallace TW, Abdullah SM, Drazner MH et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 144: 275– 281.

41. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/ World Health Organization task force on standardization of clinical nomenclature. Circulation 1979; 59: 607– 609.

42. Wu AH, Apple FS, Gibler WB et al. National academy of clinical biochemistry standards of laboratory practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45: 1104– 1121.

43. Wu AH, Jaffe AS. The clinical need for high‑sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J 2008; 155: 208– 214.

44. Wu AH, Lu QA, Todd J et al. Short‑ and long‑term biological variation in cardiac troponin I measured with a high‑sensitivity assay: implications for clinical practice. Clin Chem 2009; 55: 52– 58.

45. Zethelius B et al. Troponin I as a predictor of coronary heart disease and mortality in 70‑year old men: a community‑based cohort study. Circulation 2006; 113: 1071– 1078.